



Role of HSV-1 and Host Immune Response on Neurodegenerative Diseases

Guest Editors:

Dr. Simone Agostini

Institution of IRCCS Fondazione
Don Carlo Gnocchi (Laboratorio
di Medicina Molecolare e
Biotech), 20162 Milan, Italy

Dr. Roberta Mancuso

IRCCS Fondazione Don Carlo
Gnocchi, 20162 Milan, Italy

Deadline for manuscript
submissions:

closed (15 November 2021)

Message from the Guest Editors

Most neurodegenerative diseases are multifactorial pathologies in which the combination of different factors plays a pivotal role. Chronic bacterial and viral infections are considered as risk factors for neurodegenerative conditions, although it is still controversial as to how they contribute to the development and progression of these devastating diseases. The possibility that HSV-1 could be involved in the pathogenesis of AD was originally hypothesized 40 years ago, and, in the last ten years, many studies have explored this possibility, focusing also on the role of HSV-1-specific host immune responses in this scenario.

For this Special Issue, we invite contributions (original reports or reviews) that explore these areas of research, especially focusing on:

- Viral and host factors contributing to the outcome of HSV-1 infection and their association with neurodegenerative diseases;
- Molecular mechanisms involved in HSV-1 reactivation and their possible role in the onset of neurodegenerative diseases;
- Epidemiologic study on the association between HSV-1 infection and neurodegenerative diseases;
- Possible development of vaccines against HSV-1.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com